Evidence map›Paper›PMID 42711500›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Patient selection for primary staging with [99mTc]Tc-PSMA SPECT/CT: influence of combined PSA and ISUP grade on detection of metastatic disease.

Knut Liepe, Tony Matti Hoang, Isabell Dietrich, Hans-Jürgen Piechota, Marcel Baehr

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Knut LiepeDepartment of Nuclear Medicine, GH Hospital Klinikum Frankfurt (Oder), Muellroser Chaussee 7, Frankfurt (Oder), 15236, 15232, Germany. Knut.liepe@klinikumffo.de.ORCID http://orcid.org/0000-0002-0938-5459
Tony Matti Hoang, Duesseldorf, Germany.
Isabell DietrichDepartment of Nuclear Medicine, GH Hospital Klinikum Frankfurt (Oder), Muellroser Chaussee 7, Frankfurt (Oder), 15236, 15232, Germany.
Hans-Jürgen PiechotaRuhr University Bochum, Johannes Wesling Hospital Minden, Hans-Nolte- Str. 1, 32429, Urology, Minden, Germany.
Marcel BaehrInstitute of Radiology, Neuroradiology and Nuclear Medicine, Ruhr University Bochum, Johannes Wesling Hospital Minden, Hans-Nolte-Str. 1, 32429, Minden, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe aim of this study was to examine the combined influence of initial PSA level (iPSA) and ISUP grade on the detection rates of [99mTc]Tc-PSMA SPECT/CT in patients undergoing primary staging of prostate cancer and to identify selection criteria. PATIENTS AND

methodsIn this retrospective study, 91 patients underwent SPECT/CT following administration of 670 MBq (range, 470-792 MBq) [99mTc]Tc-MIP-1404. Detection rates of the primary tumour, pelvic lymph node metastases and distant metastases were determined together with imaging biomarkers. Univariate and multivariate nominal logistic regression analyses identified predictors of metastatic disease.

resultsBoth iPSA level and ISUP grade were independent predictors of metastatic disease (p

conclusionPatient selection for [99mTc]Tc-PSMA SPECT/CT may be improved by incorporating ISUP grade and iPSA, particularly ISUP grades 4-5 with iPSA > 20 ng/ml and ISUP grades 1-3 with iPSA > 50 ng/ml. Distinct patterns of metastatic spread were observed according to both ISUP grade and iPSA. Where PSMA PET/CT is unavailable, [99mTc]Tc-PSMA SPECT/CT may represent a valuable alternative for primary staging of selected patients with PCa.

Indexed as

[99mTc]Tc-PSMAMIP-1404Primary stagingProstate cancerPSASPECT/CT

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.